Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The dynamic multiple sclerosis (MS) market in the United States features more than a dozen high-cost branded (and one generic) disease-modifying therapies (DMTs) and an active pipeline. As the market continues to evolve, a shift towards greater emphasis on value assessment is coming; recent entrant Ocrevus offers a strong clinical profile at a compelling price and as generic versions of entrenched DMTs for relapsing forms of MS (Teva’s Copaxone 40 mg 3TW, oral agents) will launch over the next few years. As these forces give payers new leverage to control surging drug costs in MS, understanding the influence of clinical metrics and value-for-dollar on market access and medical practice—as well as the intersection of these forces and stakeholders—is key for developers of novel or next-generation DMTs. Multiple Sclerosis | Access & Reimbursement | US provides in-depth insight regarding the current and future impact of payer policy on physician prescribing behavior and DMT usage patterns.
Questions Answered in this Report:
Markets covered: United States.
Methodology: Surveys of 100 neurologists and 30 managed care company officials, including 15 pharmacy directors and 15 medical directors, in February 2017.
Indication coverage: Multiple sclerosis.
Key drugs covered: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Glatopa, Lemtrada, Plegridy, Tecfidera, Tysabri, Zinbryta, Ocrevus, ozanimod, siponimod
Key companies mentioned: AbbVie, Bayer HealthCare, Biogen, Celgene, EMD Serono, Novartis, Pfizer, Roche/Genentech, Sanofi/Genzyme, Teva